SecBot SecBot
425 ·Filed Aug 17, 2026

FULC

Fulcrum Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed3mo ago SEC0001193125-26-353280
Rule 425 M&A communications
Actionable Insight ▲ Bullish

The $270M cash dividend creates a near-term floor for FULC shares. Traders should monitor the spread between current price and the implied value of the cash dividend plus the stub equity. Key catalysts: Fulcrum stockholder vote, HSR clearance, and S-4 effectiveness. The stub value of the ~5% stake in Slate's pipeline (lead candidate SLTE-1009) is highly speculative and will determine long-term upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.84
T+0 close · Aug 17, 2026 · via day close
Latest settled
−3.13%
T+60 · $3.72
Vs SPY
−0.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $3.84entry
  2. T+1 · 3mo ago +0.78%α +1.46% · $3.87
  3. T+5 · 3mo ago 0.00%α +1.19% · $3.84
  4. T+20 · 2mo ago −1.56%α +0.42% · $3.78
  5. T+60 · 7d ago −3.13%α −0.18% · $3.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Slate in an all-stock reverse merger. Fulcrum is valued at $31.3M and Slate at $350M, with a concurrent $245M PIPE led by Frazier Life Sciences. Pre-merger FULC stockholders will receive a special cash dividend of approximately $270M (subject to adjustment) and will own ~5% of the combined company, which will be renamed Slate Medicines and trade under the ticker SLTE. The deal is expected to close in Q4 2026.

Key Financial Metrics

Deal Value
$350.0M
Deal Type
merger

Key Facts

  • Fulcrum valued at $31.3M, Slate at $350M in all-stock merger
  • $245M concurrent PIPE from Frazier Life Sciences, Forbion, RA Capital, and others
  • Pre-merger FULC stockholders to own ~5% of combined company on a fully-diluted basis
  • FULC stockholders to receive ~$270M special cash dividend (subject to adjustment based on net cash)
  • Combined company to be renamed Slate Medicines, Inc. and trade under ticker SLTE
  • Slate's management team to operate the combined company; Slate's board to control
  • Expected closing in Q4 2026; subject to stockholder approvals, HSR clearance, and Nasdaq listing
  • Slate's lead product candidate SLTE-1009 mentioned in forward-looking statements

Financial Impact

FULC stockholders to receive ~$270M cash dividend (~95% of current $285M market cap) plus a ~5% equity stake in the combined company; Slate valued at $350M with $245M PIPE providing cash runway into 2029

cash dividendownership dilutionmarket capitalization

Risk Factors

  • Deal may fail to close (requires Fulcrum stockholder approval, HSR clearance, Nasdaq listing)
  • Cash dividend amount subject to downward adjustment based on Fulcrum's net cash at closing
  • The 5% stub stake in the combined company has uncertain value given Slate's early-stage pipeline
  • Termination fee of $10M payable by Fulcrum to Slate under certain circumstances

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-353280
Document: 0001193125-26-353280-index-headers.html0001193125-26-353280
Document: 0001193125-26-353280-index.html0001193125-26-353280
Document: 0001193125-26-353280.txt0001193125-26-353280

Track record

23 reports on FULC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026